Denali Therapeutics (DNLI) Gains from Sales and Divestitures (2017 - 2018)
Denali Therapeutics (DNLI) reported Gains from Sales and Divestitures of $200000.0 for Q1 2018, down 60.0% year-over-year from $500000.0 in Q1 2017, and down 60.0% quarter-over-quarter from $500000.0 in Q1 2017.
Denali Therapeutics (DNLI) Gains from Sales and Divestitures (2017 - 2018) Analysis & Trends
Denali Therapeutics (DNLI) has 2 years of Gains from Sales and Divestitures data on file, last reported at $200000.0 in Q1 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Denali Therapeutics | 4.35 Bn | 4.35 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2018 | 200,000.00 |
| Mar 31, 2018 | 200,000.00 |
| Mar 31, 2017 | 500,000.00 |
| Mar 31, 2017 | 500,000.00 |